Cell and gene therapy offer a transformative approach in improving function and fighting disease. While an innovation in care, the industry is grappling with uncertainties regarding the long-term clinical benefits and high costs of these treatments.
Long-term monitoring of cell and gene therapies is important in ensuring efficacy and durability of response. For dates of service beginning Oct. 1, 2023, providers are required to comply with long-term monitoring requirements including requests for follow-up clinical data and/or attestation of clinical outcome.
This requirement is outlined in Harvard Pilgrim Health Care’s Commercial and StrideSM (HMO)/(HMO-POS) Provider Manuals. We’ve also updated the Providers sections of the Tufts Health Plan Provider Manuals.
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer